Atherosclerosis is the formation of plaques containing lipids, cells, debris and scar tissue in the intima of arteries. As the main pathological process underlying myocardial infarction, angina, heart failure and stroke, atherosclerosis has been the leading cause of morbid-
ity and mortality in the Western world for over half a century and is now the top cause of death globally 1 . The prominent role of vascular smooth muscle cells (VSMCs) in atherosclerosis was established in the 1960s, as soon as electron microscopy made the identification of smooth-muscle-like cells in the media of normal arteries possible 2 . These studies also ascertained that the majority of cells in atherosclerotic plaques had characteristics of VSMCs but with altered phenotypes [3] [4] [5] . However, the perception of how VSMCs contribute to atherosclerotic plaque development, remodelling and stabilization has changed substantially over the past 50 years (Box 1), and studies published in the past decade have questioned long-standing assumptions about the identity of cells in atherosclerotic plaques, demanding a re-evaluation of the role of VSMCs in atherosclerosis. In this Review, we aim to redress outdated perceptions concerning the role of VSMCs in atherosclerosis by critically evaluating the studies on the origin and fate of VSMCs in atherosclerosis and providing a holistic account of the evidence for the role of VSMCs as the disease progresses.
Identification of VSMCs
VSMCs are defined on the basis of anatomical localization (within the vasculature) and functionality. In healthy arteries, VSMCs are located in the medial layer, where they are responsible for arterial contraction and production of extracellular matrix (ECM) and have important roles in compliance and elastic recoil of the artery in response to changing haemodynamic conditions. VSMC functions are key determinants of the properties of vessels throughout the arterial tree; VSMC-derived elastin is crucial for elastic recoil in large elastic arteries (such as the aorta), and VSMC contraction is largely responsible for modulating arterial diameter in muscular arteries and arterioles (the latter being of great importance to systemic arterial resistance). Functionality is usually inferred from a combination of characteristics, including morphology and expression of 'VSMC-specific' , function-associated markers (which are typically proteins and glycosaminoglycans). In healthy arteries, VSMCs have a fusiform shape, express contractile proteins (including α-smooth muscle actin (αSMA) and smooth muscle myosin heavy chain (SMMHC; also known as myosin 11 (MYH11)), which are organized into myofilaments) and secrete ECM macromolecules, including elastins, collagens and proteoglycans. Most studies to date have relied on these markers [6] [7] [8] [9] or on gene expression profiles 10 1 and Ziad Mallat 1,2,3 * Abstract | Vascular smooth muscle cells (VSMCs) are a major cell type present at all stages of an atherosclerotic plaque. According to the 'response to injury' and 'vulnerable plaque' hypotheses, contractile VSMCs recruited from the media undergo phenotypic conversion to proliferative synthetic cells that generate extracellular matrix to form the fibrous cap and hence stabilize plaques. However, lineage-tracing studies have highlighted flaws in the interpretation of former studies, revealing that these studies had underestimated both the content and functions of VSMCs in plaques and have thus challenged our view on the role of VSMCs in atherosclerosis. VSMCs are more plastic than previously recognized and can adopt alternative phenotypes, including phenotypes resembling foam cells, macrophages, mesenchymal stem cells and osteochondrogenic cells, which could contribute both positively and negatively to disease progression. In this Review , we present the evidence for VSMC plasticity and summarize the roles of VSMCs and VSMC-derived cells in atherosclerotic plaque development and progression. Correct attribution and spatiotemporal resolution of clinically beneficial and detrimental processes will underpin the success of any therapeutic intervention aimed at VSMCs and their derivatives. identification of VSMCs. However, as a necessary corollary of their role in tissue homeostasis and repair, VSMCs have considerable phenotypic plasticity in atherosclerosis, in response to injury, and in culture in vitro, which is often accompanied by marked changes in cell morphology and expression of 'VSMC-specific' markers. Therefore, defining the cell type on the basis of functionality or 'specific' markers as a proxy for cell identification is problematic and has confounded studies on the true extent of the role of VSMCs in atherosclerosis 11 .
Developments in genetic engineering have enabled specific labelling of VSMCs in mice, making fate mapping and lineage tracing of VSMCs possible. For example, inducible VSMC-labelling systems, such as a tamoxifen-inducible recombinase driven by promoters of 'VSMC-specific' genes 12 (typically MYH11 (ref. 13 ) or TAGLN [14] [15] [16] ) combined with reporter proteins 17, 18 , facilitate specific and stable labelling of VSMCs at baseline and enable unambiguous tracing of VSMCs and VSMC-derived cells during atherogenesis, even when VSMC characteristics might otherwise be lost or gained 11, [17] [18] [19] [20] [21] [22] [23] [24] . This elegant approach has led to important advances in our understanding of the functional consequences of developmental origin, plasticity, clonality and, ultimately, fate of VSMCs in plaques, providing evidence for a more complex and prominent role for VSMCs and VSMC-derived cells in atherosclerosis than previously thought.
Origin of VSMCs
VSMCs are derived from multiple distinct progenitor cells in embryogenesis (Box 2), with little or no mixing between different lineages [25] [26] [27] , resulting in anatomical segmentation across the arterial tree. Furthermore, evidence indicates the presence of positional identity among VSMCs along the anterior-posterior, dorsoventral and right-left axes of the embryo [28] [29] [30] . Embryonic lineage can have important functional consequences; for example, VSMCs show lineage-dependent responses to important signalling pathways such as transforming growth factor-β (TGFβ) 31, 32 , platelet-derived growth factor (PDGF) 33 , myocardin-related transcription factor B (MRTF-B) 34, 35 , nuclear factor-κB (NF-κB) 36 and angiotensin II 37 . These findings exemplify a fundamental limitation in defining VSMCs on the basis of 'VSMC-specific' , function-associated markers, which can be similarly expressed in all VSMC lineages (potentially evoked through different pathways that converge on the same set of 'VSMC-specific' genes, as detailed in Box 3), whereas different VSMC lineages can have distinct functional characteristics.
Lineage-tracing studies have unambiguously demonstrated that VSMCs contribute substantially to plaque formation in murine models of atherosclerosis, generating 30-70% of all plaque cells 11, [18] [19] [20] 22, 23 . In particular, most αSMA + cells within the fibrous cap are positive for VSMC-lineage label [38] [39] [40] , refuting earlier ideas 41, 42 that bone-marrow-derived cells generate αSMA + cells. VSMC-derived cells that express mesenchymal stem cell markers, in particular stem cell antigen 1 (SCA1; also known as LY6A), have also been identified in the healthy artery media 43 and in atherosclerotic plaques 11, 43 and might represent a plastic intermediate population that is readily responsive to inflammation and capable of generating contractile or phenotypically switched VSMCs 43 . However, these studies do not rule out a contribution from other sources of progenitor cells to plaque VSMCs (Box 2).
Evidence for clonality (discussed below) of VSMCs and VSMC-derived cells in plaques indicates that the majority of plaque cells are derived from recruitment and proliferation of local VSMCs, and the anatomical localization of different developmental origins of VSMCs (and perhaps other cell types, such as pericytes and endothelial cells) might contribute to the anatomical localization of atherosclerosis susceptibility 44 . This idea is supported by the finding that segments of aorta from atherosclerosis-prone and atherosclerosis-resistant regions maintain their atherosclerosis susceptibility after transplantation to alternative sites 45 . Definitive evidence of similar anatomical segmentation of VSMC populations in humans is currently lacking, but the concept is supported in part by studies showing that human arteries are composed of clonal patches of VSMCs [46] [47] [48] . Furthermore, advances in the understanding of the development of different VSMC lineages in vivo have led to the generation of VSMCs from stem cells in vitro 49 , which will facilitate better disease modelling in human cells in vitro 50 .
Plasticity of VSMCs
VSMCs have a fully functional, differentiated phenotype in healthy vessels, yet retain remarkable plasticity. De-differentiation, modulation or phenotype switching of VSMCs is characterized by reduced myofilament density and lower expression of contractile proteins. De-differentiated VSMCs have higher expression of ECM components and ECM-remodelling enzymes, have increased levels of secretory organelles and express pro-inflammatory cytokines 51 . Consequently, phenotypically switched VSMCs are often referred to as 'synthetic' , whereas VSMCs expressing high levels of contractile proteins are generally described as 'contractile' (although these definitions imply explicit functional changes that are usually only inferred and very rarely quantified). Activation of VSMC proliferation and migration has also been associated with the synthetic, de-differentiated state, but coordinated regulation of these processes has not been documented, and mitotic VSMCs with high levels of contractile proteins have been observed 52, 53 .
Phenotypic switching is a reversible process, at least in the early stages. For example, a transient loss of contractile protein expression is observed after vascular
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• vascular smooth muscle cells (vSmCs) and vSmC-derived cells are a major source of plaque cells and extracellular matrix at all stages of atherosclerosis. • vSmCs contribute to many different plaque cell phenotypes, including extracellular-matrix-producing cells of the fibrous cap, macrophage-like cells, foam cells, mesenchymal stem-cell-like cells and osteochondrogenic cells. • Progress has been made in identifying the source of vSmCs and vSmC-derived cells in atherosclerotic plaques, highlighting the importance of the developmental origin, clonal expansion and phenotype switching of vSmCs in atherosclerosis.
Lineage tracing
Technique that enables the fate of labelled cells to be traced in vivo to allow the identification of progeny cells.
Mesenchymal stem cell
Multipotent stromal cell.
Phenotype switching
Process by which vascular smooth muscle cells (VSMCs) alter their phenotype, often inferred through decreased expression of VSMC-specific genes encoding contractile proteins and/or increased expression of markers typical of synthetic VSMCs or other cell types.
www.nature.com/nrcardio injury, followed by re-establishment of the contractile phenotype after vessel repair 54 . VSMCs with phenotypes across a spectrum ranging from contractile to synthetic states have also been observed both in vivo 53 and in VSMC cultures in vitro 55, 56 , illustrating that phenotypic switching is not a binary process. VSMC heterogeneity in morphology and gene expression 43, 57 is also seen in healthy vessels, including detection of rare, atypical VSMCs positive for SCA1 and expressing genes associated with phenotypic switching 43 . At the molecular level, the VSMC phenotype is governed by transcription factors -including myocardin-serum response factor (SRF) 58 and Krüppel-like factor 4 (KLF4) 11 , which integrate input from the environment (including growth factors, cytokines and lipid mediators, and contact with the ECM and other cells) -and is regulated at multiple levels, including by epigenetic mechanisms (Box 3). Lineage-tracing studies have revealed that VSMCs have greater than anticipated plasticity in atherosclerosis (TaBle 1) . A large proportion of reporter-expressing, VSMC-derived cells within atherosclerotic plaques do not have detectable levels of the contractile smooth muscle cell marker αSMA 11, 20 . Instead, some reporterexpressing cells in the plaque were positive for lysosomeassociated membrane glycoprotein 2 (LAMP2; also known as CD107b and MAC3) 20 , galectin 3 (GAL3; also known as MAC2) 11 and CD68 (ref. 17 ), which are markers that have been previously used to study macrophages in atherosclerosis. Stimulation of VSMCs in vitro with cholesterol similarly induces expression of macrophage-associated
Box 1 | Historical perspective on VSMCs in atherosclerosis
The development of antibodies for 'vascular smooth muscle cell (vSmC)-specific', function-associated markers, such as α-smooth muscle actin (αSmA) [6] [7] [8] [9] , greatly facilitated immunohistological studies of vSmCs in atherosclerotic plaques in animal models 203, 204 and humans 98, 103 . These studies, alongside data on in vitro culture models 56 and models of arterial injury, such as balloon angioplasty, revealed that vSmCs have great phenotypic plasticity and undergo 'phenotypic switching' from contractile to proliferative synthetic phenotypes [205] [206] [207] . Phenotype switching and proliferation of vSmCs in response to arterial injury and lipid infiltration into the arterial wall were considered the main pathological processes underlying atherosclerotic plaque development 207 .
Studies in the 1990s characterized the role of vSmC proliferation, migration, apoptosis and phenotype switching in atherogenesis 208 and revealed that vSmCs can give rise to foam cells 4,5,102 and osteochondrogenic cells 154 . However, detailed post-mortem analyses of culprit plaques in sudden cardiac death established that the integrity of the fibrous cap, comprising mostly αSmA + cells and associated extracellular matrix (eCm), is critical to stabilize and protect atherosclerotic plaques from rupture, a major cause of the clinical sequelae of atherosclerosis 142, 163, 168 . These studies also highlighted the role of immune cells, particularly macrophages, and inflammation as the main drivers of plaque development 169 . Thus, the prevailing model has been that vSmCs contribute to the cellularity and inflammation of the developing plaque but have a predominantly beneficial role in its stabilization through the generation of the fibrous cap 209 (see the figure) .
In the past decade, studies applying fate-mapping and lineage-tracing techniques have revealed the limitations of relying on 'vSmC-specific', function-associated markers to infer vSmC identity 11, 17, 18 . Furthermore, they have exposed the extent to which use of these markers can lead to false-negative and false-positive identification of vSmCs, as well as the oversimplification of vSmC heterogeneity and functions in atherosclerotic plaques. Foam cells observed by light microscopy in experimental and human atherosclerosis 210, 211 Benditt & Benditt propose that plaque VSMCs arise from clonal expansion 46 The 'vulnerable plaque' concept is developed; studies of culprit plaques in cardiac deaths identify the integrity of the fibrous cap (produced by VSMCs) to be essential to plaque stability 163, 168, 214 Ross develops further the 'response to injury hypothesis' , emphasizing the role of PDGF-mediated VSMC proliferation 207 (first described to derive from EC injury and platelet activation 213 and later updated to include macrophage-derived PDGF 129 )
First lineage-tracing studies 11, 17, 18 that revealed a much more substantial role for VSMCs in atherosclerosis than previously thought, contributing to macrophage-like cells, foam cells, osteochondrogenic cells, MSC-like cells and ECM-producing αSMA + cells of the fibrous cap The 'response to retention hypothesis' is proposed 113 and supported by the identification of the central role of ApoB-containing lipoproteins 101 Multicolour, lineage-tracing studies show that multiple cell phenotypes in plaques derive from a common ancestor, revealing the true extent of VSMC clonality in plaques 20, 22 The CANTOS trial establishes a causal role for inflammation in the pathogenesis of atherosclerosis 197 Development of Apoe -/and Ldlr -/mouse models of atherosclerosis 203, 204 genes 55,59 and promotes a phagocytic phenotype 11 . VSMC-derived cells in human atherosclerotic plaques were also found to express CD68 (ref. 11 ), consistent with previous studies detecting cells co-expressing CD68 and αSMA in human atherosclerotic plaques 60, 61 . These results support the hypothesis proposed by Wissler in 1968 that at least a subset of foam cells in atherosclerotic plaques are derived from VSMCs 62 . This concept should be considered when interpreting studies on macrophage function that rely only on marker expression. Similarly, VSMCs have been proposed to generate osteochondrogenic cells and mesenchymal stem cell-like cells in atherosclerotic plaques on the basis of the expression of mineralizing ECM proteins 63, 64 and SCA1 and endoglin 11 , respectively. The expanded plasticity of VSMCs in atherosclerosis was confirmed by transcriptional profiling of individual VSMC-lineage cells in mouse atherosclerotic plaques, revealing subpopulations of cells expressing SCA1, CD68 and the chondrocyte-related proteins transcription factor SOX9 and chondroadherin 43 .
Clonality of VSMCs
The combination of multicolour recombination markers (such as the confetti or rainbow system 18, 22 ) with genetic lineage tracing of VSMCs has demonstrated that, surprisingly, VSMC-derived cells in mouse atherosclerotic plaques are generated by clonal expansion of few cells within the vessel wall 17, 20, 22, 23 . By contrast, most medial cells do not contribute to atherosclerotic plaque formation in mice and the role of VSMC migration independent of proliferation in this process is limited 20 . Indeed, phenotypically distinct VSMC-derived cells in mouse atherosclerotic plaques are generated from a common 'ancestor' . Observations of atherosclerotic plaques at different time points suggest that, in mice, VSMCs first generate the fibrous cap, followed by phenotype switching in the lesion core 23 , but this observation remains to be tested experimentally.
The molecular mechanisms underlying clonality are yet to be established, but macrophage-secreted factors have been implicated in this process. For example, bone-marrow transplantation from β3-integrindeficient mice into Apoe −/− mice results in polyclonal VSMCs and VSMC-derived cells in the atherosclerotic plaque 23 , and conditioned media from cultured macrophages deficient in β3 integrin is more mitogenic to VSMCs than conditioned media from wild-type macrophages 23 . VSMCs in the early-stage fibrous cap are highly proliferative and express αSMA, SMMHC and, importantly, platelet-derived growth factor receptor-β (PDGFRβ) 23 , akin to the primed PDGFRβ + VSMC progenitors reported in models of hypoxia-induced pulmonary hypertension, which clonally expand in a
Box 2 | Embryonic origins of VSMCs and sources of VSMC progenitors in adults VSMC progenitor cells in embryogenesis
During embryonic development, medial vascular smooth muscle cells (vSmCs) -and in some instances pericytes 215 -arise from local progenitor cells, of which there are multiple distinct cell lineages distributed across the arterial tree (see the figure, part a). In mice, more than eight distinct progenitor cell populations have been identified 44, 216, 217 . The aortic root and outer medial layers of the ascending aorta derive from the second heart field 26, 28 ; the inner medial layer of the ascending aorta, aortic arch, ductus arteriosus, innominate and right subclavian arteries and right and left common carotid arteries derive from the neural crest 25 ; the descending aorta derives from paraxial (somatic) mesoderm 218 ; and the coronary arteries derive from pro-epicardium, which derives from lateral plate mesoderm 219 .
VSMC progenitor cells in adults
Potential vSmC progenitor populations have also been identified in the media in the adult mouse, including vSmC-derived cells expressing stem cell antigen 1 (SCA1) and other mesenchymal stem cell markers 11, 43 (see the figure, part b) . These cells might be an intermediate population derived from phenotypic switching, which can give rise to different vSmC-derived cell phenotypes 43 . other potential vSmC progenitor cells include a population of adventitial cells located close to the medial boundary, which express mesenchymal stem cell markers (such as SCA1) and are responsive to sonic hedgehog signalling (are GlI1 + ) 27, [220] [221] [222] , and pericytes 223, 224 , which are vSmC-like cells of the microvasculature.
Importantly, studies have shown that progenitor cells with distinct origins can achieve a common vSmC fate with respect to expression of 'vSmC-specific', function-associated markers (through pathways discussed in Box 3) but are nonetheless distinct with respect to other functional characteristics, such as responses to growth factors. 
Embryonic lineages
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PDGF-dependent manner 65, 66 . This observation highlights a potential role for PDGF signalling in clonal expansion of VSMCs and demonstrates that the study of VSMC clonal expansion in other vascular conditions 20,65,67 might be relevant for further mechanistic dissection in atherosclerosis. The small number of VSMCs contributing to atherosclerotic lesion formation raises the question of whether disease-associated proliferation results from activation of specific cells that are primed to respond to injury (discussed previously 68 ). Supporting this idea, transcriptional profiling of VSMCs from healthy blood vessels revealed substantial heterogeneity in the expression of genes associated with vascular disease, suggesting the existence of VSMC subtypes 43, 57 . Alternatively, clonality might rely on selection of VSMCs with equal plasticity, on the basis of location (for example, proximal to breaks in the internal elastic lamina and/or to mitogenic signals) or differential capacity for survival or senescence (see below). A role for pathways of lateral inhibition, which are common in development, has also been proposed 22 . Importantly, these possibilities are not mutually exclusive, and the underlying mechanism is likely to be genetic (somatic mutations) and/or epigenetic changes in the expanded VSMCs relative to non-expanded VSMCs.
Evidence that somatic mutations underlie clonal expansion in both malignant and non-malignant tissues
Box 3 | Molecular mechanisms underlying VSMC plasticity
Transcription factors
Myocardin. myocardin (mYoCD) family proteins drive the expression of contraction-related genes 58 . mYoCD is a cofactor for serum response factor (SRF), which binds to CArG-box elements within the promoters of contraction-related genes (see the figure) . most environmental cues and signalling pathways affecting vascular smooth muscle cell (vSmC) function alter the expression and/or activity of mYoCD 225, 226 .
KLF4. Krüppel-like factor 4 (KlF4) represses the expression of contraction-related genes through several mechanisms, including by binding to G/C repressor elements and by inhibiting SRF binding to CArG-boxes (see the figure). KlF4 inhibits proliferation; vSmC-specific deletion of DDIT3 leads to decreased vSmC proliferation through increased expression of KlF4 (ref. 227 ). Importantly, vSmC phenotype switching is KlF4-dependent. KlF4 is required for induction of progenitor cells before clonal expansion of pulmonary vSmCs in hypoxia 65, 66 , and vSmC-specific deletion of KlF4 in Apoe −/− mice results in reduced numbers of vSmC-derived, macrophage-marker and mesenchymal stem-cell-markerpositive cells in atherosclerotic plaques 11 .
Extracellular stimuli
The vSmC contractile phenotype is promoted by transforming growth factor-β (TGFβ) signalling, whereas platelet-derived growth factor (PDGF) induces KlF4 expression, vSmC proliferation and phenotypic switching to a synthetic phenotype (see the figure) . other growth factors, including WNT, also promote proliferation and migration of vSmCs. Pro-inflammatory cytokines (such as Il-1 and tumour necrosis factor (TNF)) alter the vSmC phenotype via nuclear factor-κB (NF-κB)-mediated and AP-1-mediated regulation of gene expression, including downregulation of mYoCD expression. Cholesterol-induced expression of macrophage-associated genes in vSmCs occurs via miR-143-miR-145, involves mYoCD and inflammatory signalling and is influenced by KlF4 (refS 59, 228 ).
Cell interactions
extracellular matrix proteins and heparin alter the vSmC phenotype 229 . Notably, deletion of the gene encoding β3 integrin in mice results in larger lesions and affects vSmC clonality in atherosclerosis 23 . Differences in how cells communicate with the environment can also explain the documented effect of stretch and shear stress on vSmC phenotype 230 .
Epigenetic regulation
The reversibility of vSmC phenotypic switching indicates a cellular memory of the contractile state. Indeed, contractionrelated genes retain the epigenetic modification histone H3 lysine 4 dimethylation (H3K4me2; which is generally associated with actively transcribed genes) after phenotypic switching 18 , and manipulation of DNA methylation and histone-modifying enzymes directly affects vSmC behaviour in murine models of vascular injury and atherosclerosis [231] [232] [233] , whereas levels of epigenetic markers are altered in human atherosclerotic plaques 234 . Non-coding RNAs also control vSmC plasticity 235, 236 , evidenced by the effect of specific microRNAs and long non-coding RNAs on vSmC biology and function 237, 238 . as a consequence of ageing is well documented 69 . Indeed, the acquisition of a particular set of somatic mutations, linked to clonal expansion, in myeloid progenitor cells has been associated with increased risk of atherosclerosis 70 . Therefore, similar mechanisms might underlie clonal expansion of VSMCs in atherosclerosis. Indeed, when clonal expansion of VSMCs was first described in atherosclerotic plaques, the process was likened to that in a smooth muscle cell tumour 46 . Epigenetic changes might influence clonal expansion of VSMCs secondary to, or independently of, somatic mutations. Such changes might reflect differences in VSMC lineage, environmental stimuli or stochastic events.
MYOCD SRF SRF CArG
Although lineage tracing has provided the most robust evidence yet for clonality of VSMCs in atherosclerotic plaques, the concept that most plaque VSMCs derive from clonal expansion, attributed to Benditt and Benditt 46 , has long been discussed 47 , particularly in the context of replicative senescence 71 .
VSMC senescence
Senescence is a protective mechanism that induces cell cycle arrest to prevent transmission of defects to progeny cells, particularly to stop malignant transformation [72] [73] [74] . Replicative senescence occurs after repeated cell division, typically after telomere erosion or damage, whereas induced senescence arises after oncogene activation, mitochondrial deterioration, DNA damage or oxidative stress. A persistent DNA damage response (DDR) is the most unified pathway leading to senescence, with sensing by the protein ataxia telangiectasia mutated (ATM) leading to p53 phosphorylation and upregulation of cell cycle inhibitors [72] [73] [74] . The cyclin-dependent kinase (CDK) inhibitor 1 (also known as p21) drives initial cell cycle arrest, enabling the repair of moderate DNA damage and re-entry into the cell cycle. However, prolonged cell cycle arrest upregulates the CDK inhibitor 2A (also known as p16 INK4A ), leading to dephosphorylation of retinoblastoma protein (pRb), causing permanent cell cycle arrest [72] [73] [74] . With every somatic cell division, approximately 20 bp or more are lost from the telomere ends of the chromosomes. Therefore, repeated cell division leads to critical shortening and erosion of the telomeres and loss of the protective shelterin complex, which results in a persistent DDR that instigates senescence.
VSMC senescence in vivo is likely to be driven by multiple pathways, including DNA damage, mitochondrial deterioration and oxidative stress, which are all present during atherosclerosis. Loss of autophagy can also drive VSMC senescence 75 . Replicative senescence is highly relevant in the context of atherosclerotic plaque VSMC clonality because the generation of all the VSMC-derived cells in advanced plaques by clonal expansion would probably cause replicative senescence. In keeping with this idea, the telomeres of VSMCs in
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VSMCs αSMA − cells αSMA , α-smooth muscle actin; AAV, adeno-associated virus; BM, bone marrow; FAP, prolyl endopeptidase FAP; GAL3, galectin 3; GFP, green fluorescent protein; HFD, high-fat diet; L AMP2, lysosome-associated membrane glycoprotein 2; MSC, mesenchymal stem cell; NA , not analysed; PDGFRβ, platelet-derived growth factor receptor-β; R26R , ROSA26 locus reporter ; RUNX2, Runt-related transcription factor 2; SCA1, stem cell antigen 1; SMMHC, smooth muscle myosin heavy chain; TAGLN, transgelin; TCF21, transcription factor 21; VSMC, vascular smooth muscle cell. a Tamoxifen-induced recombination before induction of atherosclerosis. human atherosclerotic plaques are markedly shortened, which correlates with disease severity 76 . Most senescent cells develop altered secretory activities known as a senescence-associated secretory phenotype (SASP) 77, 78 . Cells with SASPs release proinflammatory cytokines (such as IL-6 and IL-1), chemokines (such as IL-8, CC-chemokine ligand 2 (CCL2; also known as MCP1) and CXC-chemokine ligand 1 (CXCL1; also known as GROα)), growth factors (such as granulocyte colony-stimulating factor (G-CSF) and fibroblast growth factor 2 (FGF2)) and proteases (including matrix metalloproteinases (MMPs) and plasminogen activator inhibitor 1 (PAI1)), which confer diverse activities 78 . IL-1α is the key driver of the SASP 79, 80 , with upstream expression of IL-1α controlled in part by ATM-ATR-mediated inhibition of the p62-directed degradation of the transcription factor GATA4 (ref. 81 ) and/or by an mTORC1-dependent pathway 82 . In a physio logical setting, SASPs act as a molecular beacon that recruit and instruct immune cells to remove senescent cells (senescent surveillance 83 ) before further mutation enables senescence bypass and, for example, re-initiation of tumour formation. However, senescent cells that are not cleared by phagocytes accumulate during ageing and disease (perhaps owing to a dysfunctional immune system or a suppressive milieu) and promote chronic inflammation that could drive atherosclerosis and/or worsen the outcome 84 .
Macrophagelike cells
Osteochondrogenic cells
MSClike cells
Although VSMC senescence occurs in human atherosclerotic plaques, proving the effects of senescent VSMCs is difficult and is hampered by technical difficulties in mouse models. For example, given that telomeres are approximately ten times longer in mice than in humans, studying mouse SASPs in vitro is problematic 85 . Furthermore, detecting senescence with the classic markers p16 INK4A and senescence-associated β-galactosidase (SABG) is also notoriously difficult in mice, particularly when both markers are expressed by macrophages in atherosclerotic plaques. Two main experimental approaches have been used to study the effect of VSMC senescence in atherosclerosis: modulation of senescence induction via the DDR and clearance of naturally occurring senescent cells with 'senolytics' . For example, VSMC-specific expression of a loss-of-function mutant of the shelterin subunit telomeric repeat-binding factor 2 (TRF2; also known as TERF2) in mice led to increased DNA damage and VSMC senescence, with bigger atherosclerotic plaques and necrotic cores, whereas expression of a gain-of-function TRF2 mutant produced opposite effects 86 . Similarly, VSMCs that lack base excision repair activity have increased oxidative DNA damage and cell senescence and promote increased atherosclerotic plaque size in mice 87 . By contrast, an intriguing study used electron microscopy to assess crystals in mouse atherosclerotic plaques proposed to be the product of X-galactosidase cleavage by SABG 84 . This study reported that >50% of plaque cells were senescent, including VSMCs, macrophages and endothelial cells 84 . Senescent cells appeared in aortic lesions after 9 days of high-fat diet, and both genetic and pharmacological elimination of p16 INK4A -positive cells reduced atherosclerotic plaque formation and progression 84 . Although the cell types that were senescent and removed by these treatments are unclear, this approach might open a new paradigm for atherosclerosis treatment.
VSMCs at different stages of disease
Histological studies of atherosclerotic plaques from human autopsy tissues have culminated in a scheme for classification of lesions that encapsulates the progression of atherosclerosis 88, 89 , and careful observations of athero sclerotic plaque composition from human autopsies and animal models have revealed that VSMCs are major contributors to plaque development at all stages (summarized in fig. 1 ). However, the role of VSMCs and the effects of VSMC proliferation or loss differ according to the stage of atherogenesis.
Pre-atherosclerosis. Diffuse intimal thickenings (DITs)
and intimal xanthomas (or fatty streaks) are considered pre-atherosclerotic plaques because they are common from birth 90, 91 and probably represent a physiological adaptation to blood flow 92 . However, the relationship between intimal xanthomas and atherosclerosis is controversial because, although these lesions localize to atherosclerosis-prone regions and some intimal xanthomas develop into atherosclerotic plaques, they are also found elsewhere in the arterial tree and sometimes regress [93] [94] [95] . By contrast, DIT distribution in young individuals is similar to that of atherosclerotic plaques in later life 90, 96 , and DITs are widely considered the most likely precursor of atherosclerotic plaques 88 .
Human DITs comprise VSMCs, proteoglycans and elastin and lack macrophages and thrombus 88, 91, 92 . VSMCs in DITs exhibit clonality 47, 91 and are thought to originate from local medial VSMCs 57 . However, the latter is difficult to prove because many lineage-tracing techniques (for example, reporter gene expression under the regulation of a lineage-specific promoter) are limited to animal models, and most mammals (including mice) do not develop DITs 97 . VSMCs in DITs are heterogeneous, but most have more synthetic organelles (rough endoplasmic reticulum, ribosomes and mitochondria) than medial VSMCs 98 , consistent with switching to a synthetic phenotype, which is supported by decreased expression of genes encoding contractile proteins 99 and increased generation of ECM components 100 . VSMCs are thought to be the major source of ECM in DITs, which accounts for much of the increase in thickness of the intima, but, importantly for the progression to atherosclerosis, DITs are rich in proteoglycans, which are crucial for the retention of apolipoproteins 101 . Furthermore, VSMCs with a synthetic phenotype metabolize lipids differently to contractile VSMCs, in part through decreased expression of cholesterol esterase and reduced levels of the cholesterol efflux transporter ATP-binding cassette transporter ABCA1 (refS 60,102 ), resulting in an increased tendency to transform into foam cells 103 .
Early atherosclerosis. The first stage in atherosclerosis is pathological intimal thickening (PIT), which is characterized by the formation of extracellular lipid pools deep in the arterial intima, underlying abundant VSMCs and ECM 88, 89 . DITs can, but do not always, progress to www.nature.com/nrcardio PITs 104 (fig. 2 ). Progression from DIT to PIT is promoted through a complex interplay between retention and oxidation of lipids, induction of inflammation and VSMC proliferation, phenotype switching and death.
The lipid pools in PIT (which are distinct from the necrotic pools of more advanced plaques) comprise lipids (including free cholesterol) amidst an ECM rich in proteoglycans (notably biglycan, versican and perlecan) and glycosaminoglycans (including hyaluronan). As the predominant cell type present in DITs, intimal VSMCs are considered to be the most important source of ECM components, and this idea is supported by findings from the analysis of the secretome of VSMCs in vitro [105] [106] [107] [108] [109] . The ECM has a central role in initiation of atherosclerosis, primarily through the interaction between the negatively charged side chains of proteoglycans (particularly chondroitin sulfate of biglycan and versican and heparin sulfate of perlecan 110 ) with positively charged apolipoproteins (especially apolipoprotein B). This interaction leads to the retention of plasma-derived lipoproteins 101, 111 , as described in the 'response to retention hypothesis' 112, 113 . Transgenic mice overexpressing biglycan in VSMCs show more lipid retention in the vessel wall and increased atherosclerosis compared with wild-type littermates 114 . Once retained in the intima, lipoproteins undergo modifications, including oxidation of LDL (oxLDL), which precedes the recruitment of macrophages 115 and initiates the inflammatory response characteristic of atherosclerosis 112 . Further evidence for this series of events was provided by a study assessing DIT and PIT, which showed that extracellular lipid pools were deep in PIT lesions, colocalizing with αSMA + cells, biglycan and versican but not with the more superficial (closer to the lumen) CD68 + cells (probably macrophages) 116 .
Progression from DIT to PIT is accompanied by loss of αSMA expression, which is likely to be due to a combination of phenotypic switching of VSMCs 11, 18, 23 and loss of VSMCs through cell death 117, 118 . For example, VSMC uptake of oxLDL and formation of VSMC-derived foam cells has been linked to induction of VSMC apoptosis 118 , and free cholesterol in the lipid pool might be derived from dead VSMCs 119 . The microcalcifications (speckles of 0.5-15 μm) that are sometimes observed within the lipid pools of PITs, typically close to the border with the media, might also be a consequence of VSMC apoptosis 51 .
Macrophages can be absent from early PITs 89 but are a defining characteristic of late-stage PITs and are crucial to the progression of PITs to fibroatheromas. Lineage-tracing studies have shown that cells expressing macrophage markers in early lesions in mice (which resemble intimal xanthomas) are mostly derived from recruited circulating monocytes 23, 120 and might also derive from proliferation of resident macrophages 121, 122 . However, the presence of cells co-expressing αSMA and CD68 in human atherosclerotic plaques indicates that VSMCs are also likely to contribute substantially to the population of cells that express macrophage markers in early plaques 5, 61 . Monocytes are recruited to PITs through the expression of adhesion molecules (including selectins, intercellular adhesion molecule 1, 
Response to retention hypothesis
Hypothesis that subendothelial retention of lipid, in the form of lipoproteins, is the initial step in atherogenesis.
NATuRe RevIeWS | CARdiOLOgy vascular cell adhesion molecule 1 and CD31) in endothelial cells 123 and the presence of chemoattractants, including chemokines (such as CCL2, CCL5 and CXCL1 (refS 120, 124 ), which are secreted by VSMCs and endothelial cells after stimulation with pro-inflammatory cytokines or oxLDL in vitro 125 ) and modified lipids (such as oxLDL 126 ). Studies in animal models have collectively revealed an essential requirement for macrophages in the progression of atherosclerosis 120, 122, 127, 128 , which is likely to involve effects on VSMC migration, proliferation (through production of factors such as PDGF 129 ) and phenotype switching 130 .
Late atherosclerosis.
PITs can progress to fibroatheromas ( fig. 3 ), which are characterized by the presence of a fibrous cap and a necrotic core, the origins of which are the extracellular lipid pools and insufficient efferocytosis of dead VSMCs and macrophages [131] [132] [133] . This phase of atherosclerosis (late PIT to early fibroatheroma) depends on extensive accumulation of macrophages on the luminal side of the lipid pools, where they phagocytose deposited lipids to become foam cells. In the absence of resolution, the ensuing inflammatory reaction is self-perpetuating; macrophages and VSMCs become foam cells, which eventually die, mostly by apoptosis but potentially through other mechanisms (Box 4) . Given that the plaque milieu suppresses efferocytosis [133] [134] [135] [136] , uncleared apoptotic cells subsequently undergo secondary necrosis with release of further inflammatory material, such as damage-associated molecular patterns (DAMPs) 137 . The accompanying healing response involves the formation of the fibrous cap, which, at least in the early stages of atherosclerosis, is a highly cellular region, rich in VSMC-derived αSMA + cells 22, [38] [39] [40] among an altered ECM that has decreased proteoglycan levels and an increase in the proportion of collagens (mostly type I and III). In early atherosclerosis, VSMCs are the predominant cell type within the plaque and are the main source of atherogenic, lipid-retentive extracellular matrix (ECM) rich in proteoglycans (biglycan, versican and perlecan) and glycosaminoglycans (hyaluronan). LDL from the circulation is retained in the arterial intima through the interaction of LDL apolipoproteins with VSMC-derived proteoglycans (chondroitin sulfate in biglycan and versican and heparin sulfate in perlecan). The retained LDL is susceptible to modifications such as oxidation (oxLDL). Uptake of oxLDL by VSMCs leads to foam cell formation and apoptosis. Activated VSMCs secrete chemokines, such as CC-chemokine ligand 2 (CCL2), CCL5 and CXC-chemokine ligand 1 (CXCL1), and contribute to the recruitment of monocytes, which differentiate to macrophages. Progression to PIT is typically associated with a decreased number of cells with VSMC markers (such as α-smooth muscle actin (αSMA) + ) and increased number of cells with macrophage markers (such as CD68 + ), probably reflecting a combination of VSMC death and VSMC phenotype switching to macrophage-like cells (as a consequence of decreased myocardin (MYOCD) and increased Krüppel-like factor 4 (KLF4) expression). ABCA1, ATP-binding cassette transporter ; ApoB, apolipoprotein B; EC, endothelial cell; ICAM1, intercellular adhesion molecule 1; PDGF, platelet-derived growth factor ; SR , scavenger receptor ; VCAM1, vascular cell adhesion molecule 1.
Early atherosclerosis
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In mice, the VSMCs in the fibrous cap are derived from medial VSMCs 22,138 that have undergone migration and proliferation in response to cytokines and growth factors, such as PDGF derived from macrophages and activated endothelial cells 23, 129, 139 . This initial stage of VSMC recruitment depends, at least in part, on the transcription factor OCT4 (ref. 21 ). In humans, both pre-existing intimal and medial VSMCs can contribute to plaque VSMCs 48 . Definitive proof that VSMCs are responsible for the production of the ECM of the fibrous cap is lacking. However, this hypothesis is consistent with colocalization of collagen synthesis and VSMCs in the fibrous cap 140 , correlation of fibrous cap thickness with VSMC phenotype in mice 11, 21, 141 and the correlation of fibrous cap stability with VSMC cell number in humans 142 . In addition, a study of VSMC-specific deletion of Col15a in mice resulted in a >70% reduction in collagen type XV content in atherosclerotic lesions, supporting VSMCs as the major source of this collagen in atherosclerotic plaques 143 . Further evidence that VSMCs are the major source of collagens in atherosclerotic lesions comes from studies in vitro, including proteomic analysis of the secretome of lipid-loaded VSMCs 109 and the induction of collagen synthesis by VSMCs in culture by TGFβ, PDGF, IL-1, angiotensin II, cholesterol, homocysteine and mechanical stretch 144, 145 .
VSMCs in the later stages of atherosclerosis have previously been thought to have an entirely beneficial role, for example, by stabilizing the plaque through the generation of the fibrous cap. However, lipid loading of VSMCs and altered interactions with the ECM lead to changes in the VSMC phenotype and to increased expression of macrophage markers in VSMCs 59 . Indeed, VSMCs contribute to 30-70% of cells expressing macrophage markers 11, 20 and to a similar percentage of foam cells 146 in mouse atherosclerotic plaques and to approximately 30-40% of CD68 + cells and 50% of foam cells in human atherosclerotic plaques 11, 60 . VSMC-specific deletion of the gene encoding the transcription factor KLF4 reduces VSMC switching to macrophage-marker-positive cells and results in a marked increase in the thickness and αSMA + cell content of the fibrous cap 11 . Although these studies have shown that VSMCs can express macrophage markers, in vitro studies of the transcriptomes of both mouse and human VSMC-derived foam cells and macrophage-derived foam cells indicate that these cell types are functionally distinct and that VSMC-derived foam cells have reduced phagocytic and efferocytic responses compared with macrophage-derived foam cells 59 . VSMCs have long been known to contribute to the inflammatory milieu of the atherosclerotic plaque through recruitment of macrophages; however, these studies strongly suggest that VSMC-derived macrophage-like cells also directly affect plaque progression.
In early fibroatheromas, calcification is observed as large granules in the necrotic core and the surrounding ECM, resulting from a number of interrelated processes, including macrophage-derived and VSMC-derived calcifying microvesicles [147] [148] [149] , release of apoptotic bodies 150 or the activity of osteochondrogenic cells 151 . As the fibroatheroma develops, the microcalcifications can coalesce into larger speckles and fragments that can form sheets or plates 149 that are visible by tomography. Fragmentation of these sheets and fibrin encapsulation can lead to the formation of calcium nodules, which protrude into the vessel lumen and precipitate thrombosis 88 . The extent of plaque calcification varies according to the vascular bed, and studies have linked this variation to the different propensities of the local, developmentally distinct VSMCs to promote calcification 152, 153 . VSMCs have long been linked to calcification 150, 154 , and osteochondrogenic conversion of VSMCs in vitro is increased by environmental cues found in atherosclerotic plaques, including phenotypic conversion 155 , apoptotic bodies 150 , oxLDL 156 and pro-inflammatory cytokines such as tumour necrosis factor (TNF) 157 , IL-1β 158 and IL-18 (ref. 159 ). Furthermore, specific genetic modulation of VSMC osteochondrogenesis in vivo leads to altered calcification in animal models of atherosclerosis [160] [161] [162] . Most convincingly, however, one study established that most of the osteochondrogenic precursor (Runt-related transcription factor 2 (RUNX2) + ) cells and chondrocyte-like (type II collagen positive) cells of mouse atherosclerotic plaques derive from VSMCs 138 .
Clinical sequelae. The major clinical sequelae of atherosclerosis depend on the anatomical site of the vascular bed involved (angina and myocardial infarction in coronary arteries and stroke in carotid arteries) and typically manifest as a result of thrombosis. The primary cause (accounting for ~60-70% of cases) of thrombosis is plaque rupture 163 , and the remaining cases are predominantly the result of plaque erosion (the latter being much more frequent in young individuals, particularly women) ( fig. 4 ). A minority (typically ~5%) are due to thrombosis forming on calcified nodules. However, thrombosis and clinical sequelae are not an inevitable consequence of atherosclerosis; analysis of autopsies has revealed that atherosclerotic plaques often show evidence of silent (non-occlusive) thrombi that have undergone repair and healing. Furthermore, the widespread implementation of clinical interventions, including lipid-lowering therapies, is changing the clini cal presentation of atherosclerosis, in association with changes in the characteristics of the 'vulnerable plaque' 164 .
As the fibroatheroma develops, so does the necrotic core; the free cholesterol content and calcification increases, and breakdown and remodelling of the fibrous cap ECM occur. The latter is thought to be principally due to the actions of proteases (in particular MMPs 165 ) but also to sulfatases and exoglycosidases that are predominantly released by macrophages 166 but can also come from VSMCs 167 . Concomitantly, VSMCs are depleted from the fibrous cap through cell death, and therefore the cap diminishes, while the growing necrotic core extends outwards, leading to thinning of the fibrous cap 168, 169 . Thin-cap fibroatheromas are defined by a fibrous cap of <65 μm and are also known as 'vulnerable plaques' because studies have shown that these plaques are highly susceptible to rupture. The underlying mechanisms of plaque rupture are ill-defined but are thought to be associated with proteolytic activity 166, 167 , mechanical stress 170 and microcalcification of the fibrous cap 149, 171 .
Plaque rupture is inversely correlated with VSMC number 142 , which is determined by proliferation,
Box 4 | Mechanisms of cell death
Apoptosis
Apoptosis is the most common form of programmed cell death (PCD) throughout development and day-to-day physiology. Apoptosis is executed by pro-apoptotic caspases (such as caspase 3 and caspase 7), with main initiation pathways controlled via the mitochondria (via BCl-2 family members) or via death receptors in the cell membrane (for example, tumour necrosis factor (TNF) receptor 1 and other TNF receptor superfamily members such as FAS). Apoptotic cells must be phagocytosed; otherwise, secondary necrosis with leakage of pro-inflammatory contents (including damage-associated molecular patterns) occurs. All major cell types within the atherosclerotic plaque have been shown to undergo apoptosis.
Autophagic cell death
Autophagy is a mechanism for the organized degradation and recycling of intracellular components within double-membraned autophagosomes that fuse with lysosomes and can be a response to stress that enables the cell to survive but can also occur as PCD. vascular smooth muscle cell (vSmC)-specific deficiency in autophagy leads to increased vSmC death and increased features of vulnerable atherosclerotic plaques 188 .
Necrosis
Necrosis is a non-programmed form of cell death characterized by catastrophic loss of plasma membrane integrity and leakage of cell contents. Apoptotic cells that are not cleared by phagocytes default to secondary necrosis. This type of cell death is difficult to identify in vivo, but ultrastructural evidence suggests that macrophage and VSMC necrosis occurs in atherosclerotic plaques.
Necroptosis
Necroptosis is a programmed form of necrosis that enables cell suicide when apoptosis is blocked (such as by viral caspase inhibitors). Necroptosis is mediated by receptorinteracting serine/threonine-protein kinase 1 (RIPK1)-RIPK3, which form the ripoptosome that activates mixed lineage kinase domain-like protein (mlKl), which destroys the plasma membrane. Increased RIPK3 and mlKl levels have been reported in human atherosclerotic plaques, but necroptosis is difficult to detect in vivo.
Pyroptosis
Pyroptosis is an inflammatory form of cell death that occurs in concert with inflammasome activation and Il-1 production, often in response to intracellular infection. Pyroptosis leads to the activation of pro-inflammatory caspases (such as caspase 1, caspase 4, caspase 5 and caspase 11), which activate Il-1 and/or the poreforming protein gasdermin D (GSDmD), and subsequent membrane permeabilization. Pyroptosis probably occurs in atherosclerotic plaques after the activation of macrophage NlRP3 inflammasomes by cholesterol crystals.
Paraptosis
Paraptosis refers to a caspase-independent mechanism of cell death that leads to cytoplasmic vacuolation and eventual osmotic lysis. To date, this type of cell death has not been described in atherosclerotic plaques.
Vulnerable plaque
atherosclerotic plaque with a phenotype associated with increased risk of rupture, also known as thin-cap fibroatheromas, defined by a thin fibrous cap (<65 μm) and a large necrotic core.
www.nature.com/nrcardio migration and death of VSMCs. Advanced atherosclerotic lesions in humans show little VSMC proliferation 172, 173 , but VSMC death, through apoptosis and necrosis (Box 4), is increased compared with normal vessels [174] [175] [176] and in unstable versus stable plaques 177 . Indeed, VSMC apoptosis has been postulated to be crucial to plaque instability 178 . Seminal work showed that VSMCs from human atherosclerotic plaques spontaneously undergo apoptosis in vitro, with insulin-like growth factor I (IGF1) and PDGF acting as survival factors 179 , and with plaque VSMCs showing reduced IGF1 receptor expression compared with medial VSMCs from non-atherosclerotic arteries 180 . Similarly, cell-to-cell contact via N-cadherin promotes VSMC survival 181 . Conversely, numerous factors that induce VSMC apoptosis have been described in atherosclerotic plaques, including cell-directed killing (by macrophages, T lymphocytes and mast cells), reactive oxygen species, DNA damage, anoikis and cholesterol. Studies of VSMC apoptosis in vivo have used mice that have either alterations in apoptotic pathways or systems to induce apoptosis. Early work showed that adenoviral-mediated expression of p53 in atherosclerotic plaques in mice led to VSMC apoptosis and cap thinning 182 . Similarly, diphtheria-toxin-mediated induction of apoptosis specifically in VSMC revealed that short-term VSMC apoptosis within established atherosclerotic plaques had no effect on plaque size but resulted in vulnerable plaques with small fibrous caps and a paucity of VSMCs and structural matrix compared with those in control mice 178 , a finding that was subsequently corroborated by many studies in which VSMC death was promoted or inhibited 167, 181, [183] [184] [185] [186] [187] . Strikingly, diphtheria-toxin-mediated induction of VSMC apoptosis alongside high-fat feeding during atherogenesis in mice results in larger atherosclerotic plaques 51 , showing that the consequences of VSMC death are more than cell loss alone, and in fact actively drives plaque growth -another well-replicated finding 167, 185, 187, 188 . A crucial controller of VSMC apoptosis in atherosclerotic plaques in vivo seems to be the survival kinase AKT1 (refS 183, 186, 187 ). Conditional ablation of Akt1 during atherogenesis in mice induces VSMC apoptosis and larger plaques, and Akt1 ablation in established plaques leads to a reduced fibrous cap. The contribution of VSMC death to plaque stability is complex and extends beyond direct cell loss, with further consequences on the local milieu (such as the initiation of calcification 150 ) and wider effects in activating the immune system. The atherosclerotic plaque environment is known to inhibit phagocytosis [133] [134] [135] [136] , and defective efferocytosis of apoptotic cells, leading to secondary necrosis and leakage of intracellular contents, has been proposed to exacerbate the inflammatory milieu 131, 132, 137 . Indeed, necrotic VSMCs potently drive inflammation via IL-1α release owing to a lack of IL-1 receptor type 2 in VSMCs, which normally binds to and inhibits IL-1α 133, 189 . Therefore, a consensus appears whereby functional VSMCs are essential to maintain the fibrous cap and thereby plaque stability, but death of VSMCs is a potent driver of atherogenesis.
A study of the VSMC transcriptome in symptomatic versus asymptomatic carotid atherosclerotic plaques has also highlighted the importance of VSMC senescence in promoting plaque instability 190 . Unstable, mature plaques show low VSMC proliferation and clear evidence of VSMC senescence 191 . Senescent VSMCs were originally thought to promote plaque instability through inaction; that is, a lack of VSMC proliferation and matrix production leads to weakening of the fibrous cap. However, senescent VSMCs establish a robust IL-1α-driven SASP comprising multiple inflammatory cytokines, chemokines, MMPs and osteogenic factors 80, 192 . Thus, the VSMC SASP can recruit mononuclear cells, induce adhesion receptor expression in endothelial cells and activate adjacent normal VSMCs 80 , effectively amplifying the effect of a small number of senescent VSMCs. Senescent VSMCs also produce less collagen and release active MMP9 (ref. 80 ), whereas BMP2 and osteoprotegerin associated with the SASP drive calcification 192 . Thus, senescent VSMCs can have a negative influence on atherosclerotic plaques through both loss of normal function and a direct effect on the local milieu. An alternative route to thrombosis and clinical sequelae is through plaque erosion. Erosion refers to the formation of a thrombus in the absence of the atherosclerotic plaque rupture at sites of endothelial denudation or disruption. The underlying atherosclerotic plaque can be an intimal thickening or fibroatheroma 88, 169 , but VSMCs are often abundant, amidst a proteoglycan-rich ECM, enriched in type III collagen, versican and hyaluronan 193 . Studies have identified an important role for hyaluronan, which upon degradation activates Toll-like receptor 2 signalling 194 , and this signalling, combined with altered shear stress, leads to endothelial cell activation and apoptosis 195 , neutrophil recruitment and thrombosis 194 . Therefore, VSMCs are implicated in the events leading to plaque erosion, in particular as the major source of hyaluronan 196 .
Future perspectives Difficulties in extrapolating studies from mice to humans.
Reconciling the results of studies of animal models with those of human atherosclerosis can be challenging, as some important differences exist in how the disease progresses in humans and animal models. This difference is exemplified in the case of DITs, which are absent in most animal models. Another fundamental difference is that fibroatheromas rarely progress to rupture in animal models, exemplified by the effects of an IL-1β-neutralizing antibody, which were deleterious on the fibrous cap in mice 141 but beneficial in reducing cardiovascular events in the CANTOS trial in humans 197 . Nonetheless, animal models have been instructive in delineating important pathways and basic principles that might underlie plaque development in humans. This is particularly true of the lineage-tracing studies in mouse models of atherosclerosis, which have unambiguously established the importance of clonality and phenotype switching of VSMCs. Combinatorial genetic-depletion models are likely to be instrumental in assessing whether biasing the phenotype of VSMC-derived cells in atherosclerosis could be a potential treatment avenue. Techniques such as mass cytometry (CyTOF) and single-cell omics (genomics, transcriptomics and epigenomics) hold great promise for high-resolution, spatiotemporal analysis of atherosclerotic plaque cells in situ and are likely to provide the conclusive counterpart data in humans for the aforementioned studies.
VSMCs and genetics of atherosclerosis.
In total, >150 loci associated with risk of coronary artery disease (CAD) have been identified from genome-wide association studies and other genetic association studies 198 , many of which are associated with the disease independently of other known risk factors. Therefore, elucidation of the underlying molecular mechanisms of atherosclerosis might reveal novel pathways and hence targets for therapeutic intervention. However, identification of causal variants is usually far from trivial; CAD risk loci are often located in non-coding regions, where the causal variant is predicted to affect regulation of gene expression, which might operate over large distances and be cell-type or context specific. Studies are ongoing to identify and functionally characterize the causal variants in each of the CAD risk loci, and in vitro studies of VSMCs are proving an invaluable resource in this quest. Integration of transcriptomic and epigenomic maps from VSMCs (and other atherosclerotic plaque cells) with those of the genetic architecture of CAD can be very informative for prioritizing variants (and potential pathways) for functional characterization 199, 200 . Unsurprisingly, given the crucial role of VSMCs in athero sclerosis, a number of loci have been predicted to modulate the risk of CAD through mechanisms specific to VSMCs 200 . Thus, studies in cultured VSMCs and VSMCs derived from stem cells 49, 201 are likely to be instrumental in the functional characterization of CAD variants. Pioneering examples of such studies include the characterization of the SMAD3 and TCF21 loci 202 .
Conclusions
The role of VSMCs in atherosclerosis extends far beyond that perceived for decades. VSMCs and VSMC-derived cells comprise a (if not the) major source of atherosclerotic plaque cells and contribute to numerous plaque cell phenotypes, including macrophage-like cells and foam cells, in addition to cells responsible for producing the atherogenic or athero-protective ECM throughout the disease process. Thus, VSMCs are implicated mechanistically at all stages of atherosclerosis, and lineage-tracing studies have established the extent and importance of VSMC clonality and phenotype switching in plaque progression. These concepts have been around for decades, but only very recently technologies for genetic engineering and imaging have converged with a deeper understanding of developmental processes to generate conclusive data in animal models. The era of single-cell omics promises to deliver the evidence as to whether and how these processes contribute to the disease in humans. A better understanding of the biology of VSMCs is required if we are to fulfil aspirations of selectively targeting 'culprit' cells or manipulating cell phenotypes for clinical benefit and/or to avert processes that are detrimental in atherosclerosis.
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